Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect

We expect investors to focus on the launch plans of Arcturus Therapeutics Holdings Inc.’s (ARCT) self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, Kostaive (ARCT-154), and updates on the pipeline when it reports third-quarter 2024 results on Nov. 7, after market close.The Zacks Consensus Estimate for revenues is pegged at $49.2 million.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Let's see how things might have shaped up for the quarter to be reported.Factors to Note Ahead of ARCT ...